Healthy Skepticism International News

Pharmacia & Upjohn Lincocin (lincomycin) and Dalacin C (clindamycin)

March 1996

Vol 14 Issue 3 Upjohn persists with its claims that Dalacin C (clindamycin) has "proven safety" and "a documented history of worldwide use and patient acceptance". A complaint to the International Federation of Pharmaceutical Manufacturers Associations and a follow-up letter to Upjohn regarding its promotion of clindamycin and Lincocin (lincomycin) for upper respiratory tract infections in the Philippines.

HS Int News index

Comments

Our members can see and make comments on this page.

Please
Click to Register

(read more)

then
Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Announcements

PharmedOut’s annual conference: Missing The Target: When Practitioners Harm More Than Heal

No Free Lunch is merging with Healthy Skepticism

Conference program: Pharma Knows Best? Managing Medical Knowledge

Prescrire’s proposals for France’s national conference on medicines policy

Pharmed Out Conference ‘Pharma Knows Best? Managing Medical Knowledge’

More announcements

What's new on this site

Next issue: Beaufour-Ipsen Smecta (smectite)

Previous issue: Servier Arcalion (sulbutiamine) and Duxaril (almitrine/raubasine)

HS Int News index

As an advertising man, I can assure you that advertising which does not work does not continue to run. If experience did not show beyond doubt that the great majority of doctors are splendidly responsive to current [prescription drug] advertising, new techniques would be devised in short order. And if, indeed, candor, accuracy, scientific completeness, and a permanent ban on cartoons came to be essential for the successful promotion of [prescription] drugs, advertising would have no choice but to comply.
- Pierre R. Garai (advertising executive) 1963